X4 Pharmaceuticals, Inc. Price & Performance (XFOR)

X4 Pharmaceuticals will execute a one-for-thirty reverse stock split effective April 28, reducing outstanding shares from about 173.6 million to 5.8 million. The move aims to boost share price and ensure compliance with Nasdaq’s minimum bid price rule after a year of significant stock declines. Analysts, however, remain optimistic on the company’s future prospects.12

X4 Pharmaceuticals will announce its first-quarter 2025 financial results and provide a corporate update on May 1. The event includes a conference call and webcast, offering investors insights into recent progress, including the ongoing Phase 3 trial for mavorixafor and commercial performance of XOLREMDI®.34

Despite recent stock volatility and a steep share price drop, analysts maintain a strong buy consensus for X4 Pharmaceuticals, with average price targets well above current levels. The company’s restructuring, product launches, and international expansion are cited as reasons for optimism, though financial risks and market penetration challenges persist.56